Trial · NCT07882225
Microneedle-based ISF Sampling Technique
NCT07882225, Not applicable, Not yet recruiting, Ascilion AB
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Microneedle-based ISF Sampling Technique. Trials, record NCT07882225. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07882225
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Microneedle-based ISF Sampling Technique
- NCT number
- NCT07882225
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 110 participants, estimated
- Lead sponsor
- Ascilion AB
- Conditions
- No Condition, Healthy Individuals
- Interventions
- PELSA System
- First posted
- 2026-10-20
- Last updated
- 2026-10-21
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Successful Collection of Dermal Interstitial Fluid | During the sampling session | Proportion of participants with successful collection of at least 1 µL of dermal interstitial fluid during one PELSA sampling session. The success proportion and its 95% confidence interval will be calculated. |
| Other | Incidence of Device-Related Serious Adverse Events | From device application through 7-day follow-up. | Number and proportion of participants experiencing device-related serious adverse events during the investigation and follow-up period. |
| Other | Participant-Reported Pain During PELSA Sampling | During and immediately after the sampling procedure (Day 1). | Procedural pain will be assessed using a participant-reported Numerical Rating Scale (NRS) ranging from 0 (no pain) to 10 (worst imaginable pain). Pain scores will be summarized descriptively across participants. |
| Other | Local Skin Reactions Following PELSA Sampling | Before and after the sampling procedure (Day 1). | Standardized photographs of the sampling site will be obtained after the PELSA procedure to document visible skin changes, including erythema, bleeding, or other local reactions. Skin findings will be evaluated descriptively. |
| Other | Detectability of Glucose in Collected Dermal Interstitial Fluid | Following dISF collection during the study visit (Day 1). | The presence of glucose in collected dermal interstitial fluid (dISF) will be assessed using a commercially available glucose measurement system (Contour Next). The proportion of samples yielding a measurable glucose result will be reported descriptively. |
| Other | Exploratory Detection of Inflammatory Proteins in Dermal Interstitial Fluid | Samples collected during the study visit (Day 1), with subsequent laboratory analysis. | A subset of 20 collected dISF samples will undergo exploratory proteomic analysis using the NULISA Inflammatory 250 panel. The analysis will assess the detectability of inflammatory proteins in dISF, including the number and proportion of protein targets detected above the assay-specific detection threshold. Results will be summarized descriptively. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07882225
GET https://conductscience.org/api/trials/v1/NCT07882225/registered